http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20100102621-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00a421ab71bd49a451d0a49d23a082c7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dd5ae6502c5b7d8ed6661616141733e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c049255e1613b88b90a0c12301c91a21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36271c181317fb5501e7b47516fe9d48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a2440c30cba7b5d34f088c44a5d0de8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bb474c866df7b81a12c3f9e1b49aef9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9ca8da6c067c0b271131da72c9e9db6 |
| publicationDate | 2010-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20100102621-A |
| titleOfInvention | Target radiotherapy |
| abstract | The present invention relates to a therapeutically labeled naphthodiantron or phenanthro [1,10,9,8-opqra] perylene-7,14-dione compound, which has an unstable nucleus and has a peripheral environment during the collapse process. By containing chemical elements or isotopes that emit radiation in a form that is stable enough to destroy cells or tissues, it enhances the treatability of warm-blooded animals undergoing necrosis-induced anti-tumor treatment when used in targeted radiation therapy. A particular advantage of the present invention is the necrosis-inducing anti-tumor, such as vascular targeting agent (VTA), by administering a therapeutically radiolabeled necrosis-affinity chemical compound small molecule in single or multiple doses to enhance the treatability. It is possible to complementally treat viable rims or tumor residues that are resistant to treatment. Examples of necrosis-induced therapies include minimally invasive tumor removal chemically performed by percutaneous injection of ethanol or acetic acid or physically by cryotherapy, microwave, integrated ultrasound, interstitial laser therapy and radiofrequency ablation (RFA); Chemotherapy with cytotoxic agents or vascular targeting agents (VTA); And radiotherapy by external or internal radiation of tumor tissues and the like. |
| priorityDate | 2007-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 302.